Assert-IQ vs cmAngio®
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Assert-IQ provides long-term, continuous monitoring and advanced arrhythmia detection through an insertable cardiac monitor, focusing on diagnosing and managing heart rhythm disorders. In contrast, cmAngio® is an AI-powered software that detects Breast Arterial Calcifications on mammograms to aid in early cardiovascular risk assessment. While both contribute to cardiovascular health, they address distinct clinical problems and utilize different data sources (physiological signals vs. medical imaging), making them complementary rather than direct competitors.
Choose Assert-IQ if…
Choose Assert-IQ if your primary goal is long-term, continuous monitoring and advanced detection of suspected heart rhythm disorders. This tool is ideal for comprehensively diagnosing and managing patients requiring extended cardiac surveillance and remote clinician alerts.
View Assert-IQ →Choose cmAngio® if…
Choose cmAngio® if you aim to leverage existing mammography data for early cardiovascular risk assessment in women. This AI-powered solution provides non-invasive detection and visualization of Breast Arterial Calcifications (BAC) to inform patient care without additional radiation or procedures.
View cmAngio® →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Assert-IQ | cmAngio® |
|---|---|---|
| Primary Function | Long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. |
| Company | Abbott Medical | CureMetrix |
| Targeted Medical Categories | Cardiology AI, Clinical Decision Support & Reference | Cardiology AI, OB/GYN AI, Radiology & Imaging AI |
| Core Technology/Method | Insertable Cardiac Monitor (ICM) system with advanced arrhythmia detection algorithms. | AI software for detecting Breast Arterial Calcifications (BAC) on mammograms. |
| Key Data Handling/Output | Bluetoothu00ae Low Energy data transmission, secure cloud-based data platform, remote monitoring capabilities, proactive clinician alerts, patient activator for symptom logging. | Provides visualization of BAC location on a scorecard, compatible with any DICOM-compliant viewer. |
| Free Trial Availability | No | Limited-time offers for no-cost implementation and service may be available. |
Videos
Demos, reviews, and walkthroughs featuring Assert-IQ and cmAngio®.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
Assert-IQ is an insertable cardiac monitor system designed for long-term, continuous monitoring and advanced arrhythmia detection to aid in diagnosing and managing patients with suspected heart rhythm disorders. In contrast, cmAngio is FDA-cleared AI software that detects Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment.
Assert-IQ is intended for patients susceptible to cardiac arrhythmias and unexplained symptoms like dizziness, palpitations, or syncope, as well as those at risk for or previously diagnosed with atrial fibrillation. cmAngio is designed for women undergoing mammography, utilizing existing screening mammograms to identify those with BAC for potential cardiovascular risk assessment.
Assert-IQ is a minimally invasive insertable cardiac monitor that continuously monitors heart rhythms and transmits data via Bluetooth Low Energy to a secure cloud-based platform. cmAngio is AI software that processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams to detect and visualize Breast Arterial Calcifications.
Assert-IQ provides long-term continuous cardiac monitoring for up to 6 years, with options for at least three or six years of battery life. cmAngio performs an AI-based assessment on individual mammogram exams, providing insights at the time of the imaging procedure, and is recommended annually with routine mammograms.
Assert-IQ offers advanced arrhythmia detection algorithms, proactive clinician alerts, and remote monitoring capabilities, including insights into PVCs, body position changes, and AF burden trending. cmAngio provides visualization of BAC location on a scorecard, enabling identification and reporting of BAC without additional radiation, which can inform cardiovascular risk assessment.